Dickkopf-1 in ankylosing spondylitis: Relation to spinal dysmobility and radiographic findings  by Elshishtawy, Heba et al.
The Egyptian Rheumatologist (2012) 34, 111–117Egyptian Society for Joint Diseases and Arthritis
The Egyptian Rheumatologist
www.rheumatology.eg.net
www.sciencedirect.comORIGINAL ARTICLEDickkopf-1 in ankylosing spondylitis: Relation to spinal
dysmobility and radiographic ﬁndingsHeba Elshishtawy a,*, Naglaa Assaf a, Naglaa Farouk ba Rheumatology & Rehabilitation Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
b Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, EgyptReceived 25 March 2012; accepted 22 May 2012
Available online 28 June 2012*
D
St
E-
Pe
an
11
htKEYWORDS
Dickkopf-1;
Ankylosing Spondylitis;
Bath Ankylosing Spondylitis
Disease Activity Index;
modiﬁed Stoke Ankylosing
Spondylitis Spinal ScoreCorresponding author. Add
epartment, Faculty ofMedicin
., Cairo, Egypt. Tel.: +20 2 2
mail address: h_f_elshishtaw
er review under responsibility
d Arthritis.
Production an
10-1164  2012 Egyptian So
tp://dx.doi.org/10.1016/j.ejr.2ress: Rh
e, Ain Sh
5320480,
y@yahoo
of Egyp
d hostin
ciety for
012.05.00Abstract Back ground: Dickkopf-1 (DKK-1) is an inhibitory molecule that regulates Wnt path-
way, which is critically important in osteoblastic new bone formation, therefore it may play a role
in the process of new bone formation in Ankylosing Spondylitis (AS).
Aim of the work: To measure serum level of DKK-1 in AS patients and study the relation
between these levels with disease activity, spinal dysmobility and radiographic ﬁndings.
Patients and methods: Thirty AS patients as well as 20 healthy subjects as a control group were
included in this study. DKK-1 serum levels were measured using ELISA technique, disease activity
was assessed using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score, radio-
graphic assessment by Bath Ankylosing Spondylitis Radiology Index-spine (BASRI-s) and modiﬁed
Stoke Ankylosing Spondylitis Spinal Score (mSASSS).
Results: DKK-1 was not correlated to ESR, CRP or BASDAI (p> 0.05) and was negatively
correlated to BASRI-s and mSASSS (p< 0.001), though DKK-1 serum level was unexpectedly
higher in patients versus control (p< 0.001). On comparing HLA-B27 positive and HLA-B27 neg-
ative patients, there were a signiﬁcant increase in BASRI-s and mSASSS and decrease in DKK-1
level in those with positive HLA-B27 (p< 0.05). On comparing patients received anti TNF therapy
and those not received anti TNF therapy, there was no signiﬁcant difference in DKK-1 level
(p> 0.05).
Conclusion: Our ﬁnding suggests dysfunction of DKK-1 in patient with AS.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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21. Introduction
Ankylosing Spondylitis (AS) is a chronic inﬂammatory disor-
der characterized by new bone formation that progressively
leads to ankylosis and functional disability [1].
Endochondral bone formation steered by initial cartilage
formation, which is then replaced by bone, seems to be an
important mechanism in AS [2,3].uction and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
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homeostasis, in particular osteoblastic new bone formation
therefore they may also play a role in the process of new bone
formation as seen in AS [4–6].
Several members of the Wnt protein family bind to a recep-
tor complex (Comprising LPR5/6 and frizzled receptor) on the
plasma membrane of mesenchymal cells and this binding sig-
nals osteoblast differentiation by engaging the intracellular
protein B-catenin [7].
Wnt signaling is modulated by several different families of
secreted negative regulators. Among those, DKK is a family of
cystein-rich proteins comprising at least four different forms
(DKK-1, DKK-2, DKK-3 and DKK-4). The best studied of
these is DKK-1, which functions as natural inhibitor of Wnt
signaling [8].
Binding of DKK-1 to LPR 5/6 receptor and a cell surface
co-receptor; Kremen-½ promotes internalization of the recep-
tor complex and dampens the Wnt signal. Deletion of a single
allele of DKK-1 increases bone mass in mice [9].
Inhibition of DKK-1 reverses the bone destructive pattern
in a mouse model of rheumatoid arthritis to the bone-forming
pattern of osteoarthritis, Diarra et al. suggested that DKK-1 is
a key regulator of joint remodeling [10,11]. A recent study re-
ported that DKK-1 levels were signiﬁcantly increased in pa-
tients with AS [12]. In contrast other investigators reported
that DKK-1 level is lower in patients with AS than in healthy
people [13]. Other investigators reported that DKK-1serum le-
vel was similar in AS patients and the control group [14]. The
aim of this study was to measure the serum level of DKK-1 in
patients with AS and to study the relation between these levels
with disease activity, spinal dysmobility and radiographic
ﬁndings.2. Patients and methods
This was a cross sectional study; it included 30 patients with
AS diagnosed according to the modiﬁed New York criteria
[15].
They used to attend the outpatient clinic of Rheumatology
and Rehabilitation Department as well as the Internal Medi-
cine Department of Ain Shams University Hospital. Twenty
age and sex matched healthy volunteers served as control
group.
2.1. Exclusion criteria
Patients having diffuse idiopathic skeletal hyperostosis, degen-
erative spondylosis, other forms of seronegative spondyloarth-
ropathes or pagets disease of the bone were excluded.
The study was approved by the local ethics committee. A
written consent was obtained from patients and control before
participating.
2.2. Patients assessment
2.2.1. Full history taking
 History of buttock pain, back stiffness, eye involve-
ment, medications received and family history was
taken. Clinical assessment for disease activity in AS was mea-
sured by the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI) [16].
2.2.2. Through clinical examination
 Clinical assessment for spinal mobility measured by the
Bath Ankylosing Spondylitis Metrology Index
(BASMI) [17].
 Clinical assessment to thoracic mobility (chest expan-
sion) according to Assessments in Ankylosing Spondy-
litis (ASAS) Working Group [18]. The difference in
centimeters to the nearest 0.1 cm between full expira-
tion and full inspiration at the nipples [19].
2.2.3. Radiological assessment was performed by
 Plain X-ray anteroposterior view of sacroiliac joints
assessed according to Bath Ankylosing Spondylitis
Radiology Index-spine (BASRI-s) [20].
 Plain X-ray lateral, anteroposterior views of cervical
and lumbar spine assessed according to modiﬁed Stoke
Ankylosing Spondylitis Spinal Score (mSASSS) [21].
2.2.4. Laboratory investigations
 Complete blood picture.
 Erythrocyte Sedimentation Rate (ESR) using Wester-
gren method.
 CRP using latex agglutination method.
 Serum calcium and phosphorus by standard conven-
tional assays.
 Bone speciﬁc alkaline phosphates by Enzyme Linked
Immunosorbent Assay (ELISA: Tandem-MP ostase,
Bechman Coulter, USA).
 Serum creatinine with synchron cx5 auto analyzer.
 Human Leukocyte Antigen (HLA-B27) typing.
 Measurement of serum DKK-1 was done by ELISA
for quantitative determination of DKK-1 in human
serum the kits were supplied from (BioVendor – Labo-
ratornı´ medicı´na, Czech Republic). Serum was stored
frozen at 80 C until measurement. Samples are incu-
bated in microtitration wells pre-coated with poly-
clonal anti-human Dkk-1 antibody. After a 60 min
incubation followed by washing, biotin labeled poly-
clonal anti-human Dkk-1 antibody is added and incu-
bated with the captured Dkk-1 for 60 min. After
another washing, streptavidin-HRP conjugate is added.
After 30 min incubation and the last washing step, the
remaining conjugate is allowed to react with the sub-
strate solution (TMB). The reaction is stopped by addi-
tion of acidic solution and absorbance of the resulting
yellow product is measured. The absorbance is propor-
tional to the concentration of Dkk-1. A standard curve
is constructed by plotting absorbance values against
Dkk-1 concentrations of standards, and concentrations
of unknown samples are determined using this stan-
dard curve.
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using SPSS (statistical program for social science version 12).
Data were expressed as range, median, mean.
Mean ± SD were used to describe quantitative data. Un-
paired t-test was performed to compare quantitative variables.
Mann Whitney test was used instead of unpaired t-test in non
parametric data. Correlation analysis using Pearson’s method
was undertaken to assess the strength of association between
two quantitative variables. The correlation coefﬁcient, denoted
symbolically ‘r’, deﬁnes the strength and direction of the linear
relationship between two variables. In all tests if (p> 0.05) it
is nonsigniﬁcant, if (p< 0.05) it is signiﬁcant and if
(p< 0.001) it is highly signiﬁcant.
3. Results
This study included 30 patients with AS; 27 males (90 %) and 3
females (10%), (mean age 35.1 ± 7.1). The controls were 20
healthy subjects, 18 males (90%) and 2 females (10%), (mean
age 33.5 ± 3.7). They were matched as regards age and sex
(p> 0.05). Among the 30 patients with AS; 30 (100%) had
back pain, 13 (43.3%) neck stiffness, 11 (36.7%) peripheral
arthritis, 2 (6.6%) uveitis. 26 patients (86.7%) were HLA-
B27 positive.Table 1 Patients’ clinical and laboratory data.
Parameter Range Mean ± SD Median
Age (years) 28–46 35.1 ± 7.1 32.5
DD (years) 1–18 7.1 ± 5.1 6.0
BASDAI 0.5–7.8 4.7 ± 1.8 4.6
BASMI 1–7.4 4.7 ± 1.8 4.9
Cervical rotation () 13–85 51.6 ± 23.2 52.0
Tragus to wall (cm) 13–38 21.3 ± 5.9 20.0
Modiﬁed Schober (cm) 0.5–7 3.3 ± 1.9 2.8
Intermalleolar (cm) 45–120 91.7 ± 25.9 95.0
Chest expansion (cm) 1–5 2.6 ± 1.1 2.0
BASRI-s 4–8 6.7 ± 1.5 7.0
mSASSS 12–68 44.6 ± 16.7 46.0
ESR (mm/h) 5–85 23.8 ± 22.2 15.0
CRP (mg/dl) 5–24 12.9 ± 8.4 12.0
Hb % (g/dl) 9.6–15 13.5 ± 1.4 13.9
RBCs (106/mm3) 4.3–5.8 5.0 ± 0.5 5.0
WBCs (103/mm3) 4–11.6 7.6 ± 2.1 7.2
Plat. (103/mm3) 201–413 273.2 ± 57.9 256.0
Creatinine (mg/dl) 0.7–1.5 0.98 ± 0.2 0.9
Ca++ (mg/dl) 8.7–10.1 9.3 ± 0.4 9.3
P++ (mg/dl) 2.7–4.1 3.2 ± 0.5 3.0
ALP (IU/L) 50.4–120 76.8 ± 18.8 78.0
DKK-1 (pg/ml) 2210–2915 2539.7 ± 234.9 2530.0
DD=Disease Duration, BASDAI = Bath Ankylosing Spondyli-
tis Disease Activity Index, BASMI= Bath Ankylosing Spondylitis
Metrology Index, Intermalleolar =Maximal Intermalleolar dis-
tance, BASRI-s = Bath Ankylosing Spondylitis Radiology Index-
spine, mSASSS = modiﬁed Stoke Ankylosing Spondylitis Spinal
Score, ESR= Erythrocyte Sedimentation Rate, CRP= C-Reac-
tive Protein, Hb %=Hemoglobin %, RBCs = Red Blood Cells,
WBCs =White Blood Cells, Plat. = Platelets, Ca++= Calcium,
P++= Phosphorous, ALP = Bone speciﬁc alkaline phosphates,
DKK-1 = Dickkopf-1.3.1. Patients’ clinical and laboratory data
Patients’ data are shown in Table 1.
3.2. Comparison between patients and control groups as regards
DKK-1
On comparing patients and control groups as regards DKK-1
mean serum levels, there was a statistically highly signiﬁcant
increase in DKK-1 levels in patients (2539.7 ± 234.9) versus
control (1635.3 ± 267.4) (p< 0.001) (Fig. 1).
3.3. Correlation studies between DKK-1 and clinical, laboratory
and radiological characteristics of AS patients
Correlation studies revealed a signiﬁcant positive correlation
between DKK-1 and serum Ca++ (p< 0.05) and signiﬁcant
negative correlation with BASRI-s and mSASSS (p< 0.001),
and no correlation with ESR, CRP, BASDAI (p> 0.05)
(Table 2, Figs. 2 and 3).
3.4. Comparison between HLA-B27 +ve and HLA-B27ve AS
patients
On comparing patients HLA-B27 positive and HLA-B27
negative, there were a signiﬁcant increase as regards disease
duration, BASRI-s and mSASSS and signiﬁcant decrease in
DKK-1 levels in HLA-B27 +ve versus HLA-B27 ve
(p< 0.05) (Table 3, Fig. 1).
3.5. Comparison between patients treated with anti TNF therapy
and those not treated with anti TNF therapy
Thirty patients (100%) received NSAIDs. Eleven patients
(36.7%) received sulfasalazine. Eighteen patients (60%) re-
ceived anti TNF therapy; 10 patients (33.3%) received ada-
limumab 40 mg every other week by SC administration, 5
patients (16.7%) received etanercept at dose 25 mg twice
weekly, 3 patients (10%) received 5 mg/kg inﬂiximab infusion
at weeks of 0, 2, 6 and 14.
On comparing patients received anti TNF therapy and
those not received anti TNF therapy, there was no signiﬁcant
differences as regards DKK-1 level (p> 0.05) (Fig. 1).4. Discussion
Syndesmophytes, vertical bony spurs, ultimately leading to a
bridge between vertebrae are a hallmark of AS. It seems that
in AS an initial bone resorptive phase may act as a stress factor
which is followed by profound endochondral bone formation,
originating from the periosteum close to the joints or interver-
tebral spaces, where mesenchymal cells are localized which
have the ability to differentiate into cartilage and bone when
they receive appropriate signals leading to bone spurs. Molec-
ularly these lesions depend on increased bone which is most
likely governed by members of TGF, BMP protein family as
well as by group of Wnt proteins [22].
The aim of this study was to measure serum level of DKK-1
which has been deﬁned as direct inhibitor of Wnt/B catenin
0.0
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Figure 1 DKK-1 serum level in AS patients and control group. Y-Axis indicates DKK-1 mean serum level. DKK-1 = Dickkopf-1,
AS = Ankylosing spondylitis, HLA+ ve = HLA-B27 positive, HLA ve = HLA-B27 negative, Anti. TNF ttt = patients received
Anti. TNF treatment, Anti. TNF no ttt = patients not received Anti. TNF treatment.
Table 2 Correlation studies between DKK-1 and clinical,
laboratory and radiological characteristics of AS patients.
Parameter r p
Age 0.018 p> 0.05 (NS)
DD 0.162 p> 0.05 (NS)
BASDAI 0.154 p> 0.05 (NS)
BASMI 0.643 p> 0.05 (NS)
Chest expansion 0.251 p> 0.05 (NS)
BASRI-s 0.748 p< 0.001 (HS)
mSASSS 0.926 p< 0.001 (HS)
ESR 0.088 p> 0.05 (NS)
CRP 0.057 p> 0.05 (NS)
Hb % 0.213 p> 0.05 (NS)
RBCs 0.191 p> 0.05 (NS)
WBCs 0.275 p> 0.05 (NS)
Plat. 0.095 p> 0.05 (NS)
Creatinine 0.134 p> 0.05 (NS)
Ca++ 0.444 p< 0.05 (S)
P++ 0.253 p> 0.05 (NS)
ALP 0.348 p> 0.05 (NS)
DD=Disease Duration, BASDAI = Bath Ankylosing Spondyli-
tis Disease Activity Index, BASMI = Bath Ankylosing Spondylitis
Metrology Index, BASRI-s = Bath Ankylosing Spondylitis Radi-
ology Index-spine, mSASSS = modiﬁed Stoke Ankylosing Spon-
dylitis Spinal Score, ESR= Erythrocyte Sedimentation Rate,
CRP= C-Reactive Protein, Hb %=Hemoglobin %,
RBCs = Red Blood Cells, WBCs =White Blood Cells,
Plat. = Platelets, Ca++= Calcium, P++= Phosphorous,
ALP = Bone speciﬁc alkaline phosphates, DKK-1 = Dickkopf-1.
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disease activity, spinal dysmobility and radiological ﬁndings.
Our study revealed a highly signiﬁcant increase in DKK-1
serum level in AS patients versus the control (p< 0.001).
Our result was similar to that of Daoussis et al. [12]. In con-
trast to our result, a recent study reported that DKK-1 levelis lower in AS patients than in healthy people [13]. A recent
study reported that DKK-1 serum level was similar in both
AS patients and control group [14]. The source of DKK-1
could be derived from the local tissue and extra articular tissue.
Previous studies have shown that DKK-1 was expressed in
synovial cells, articular cartilage and subchondral bone osteo-
blast in OA knees [10]. Unexpectedly, DKK-1 was found to be
high in our study, this may be hinged to one of the following; a
compromised DKK-1 function, or reduced binding of DKK-1
to its receptor in AS which may lead to unopposed increased
Wnt signaling that may have pathogenic implications in the
disease, or the presence of soluble DKK-1 inhibitor (either
an auto antibody against DKK-1 or soluble receptor) in the
serum of patients with AS [12], other pathways such as
TGFB/BMP protein pathways maybe the main regulator con-
trolling new bone formation in AS [23].
Correlation studies showed no signiﬁcant correlation be-
tween DKK-1 and ESR and CRP (p> 0.05). Other investiga-
tors reported same results [12,24] which indicate that
expression of this Wnt antagonist is not linked to acute phase
response. Also there was no signiﬁcant correlation between
DKK-1and BASDAI (p> 0.05). Novel data arising from ba-
sic research and clinical studies suggest that inﬂammation and
new bone formation in AS are two largely independent pro-
cesses [25,26].
Conﬂicting data on DKK-1 serum level in our results
though it was unexpectedly higher in AS patients versus the
control, correlation studies revealed a signiﬁcant negative cor-
relation between DKK-1 levels and BASRI-s and mSASSS
(p< 0.05). These results suggest a complex effect of DKK-1
on Wnt signaling pathway and structural remodeling in AS.
In accordance with our result Heiland et al. concluded that
AS patients with no syndesmophyte formation show signiﬁ-
cantly higher functional DKK-1 level [24]. Also Uderhardt
et al. reported that DKK-1 blockade promoted expression of
collagen type ‘x’, the formation of hypertrophic chondrocyte
and ankylosis of sacroiliac joints [27]. Others found no corre-
Table 3 Comparison between HLA-B27 + ve and HLA-B27 ve AS patients.
Parameter HLA-B27 + ve n= 26 mean ± SD HLA-B27 –ve n= 4 mean ± SD t p
Age (years) 35.6 ± 7.7 39.0 ± 2.8 0.600 p> 0.05 (NS)
DD (years) 16.88a 6.5a 2.208b p< 0.05 (S)
BASDAI 4.7 ± 2.0 4.9 ± 0.5 0.180 p> 0.05 (NS)
BASMI 5.0 ± 1.6 2.5 ± 2.1 2.05 p> 0.05 (NS)
Chest expans. (cm) 2.4 ± 1.13 3.5 ± 0.7 1.281 p> 0.05 (NS)
BASRI-s 7.0 ± 1.29 4.5 ± 0.7 2.621 p< 0.05 (S)
mSASSS 48.8 ± 13.6 17.0 ± 7.1 3.168 p< 0.05 (S)
ESR (mm/h) 16.12a 11.5a 0.983b p> 0.05 (NS)
CRP (mg/dl) 16.65a 8.0a 1.899b p> 0.05 (NS)
Hb % (g/dl) 13.3 ± 1.5 14.4 ± 0.6 0.962 p> 0.05 (NS)
RBCs (106/mm3) 5.02 ± 0.5 5.0 ± 0.28 0.062 p> 0.05 (NS)
WBCs (103/mm3) 7.5 ± 1.9 8.9 ± 3.9 0.841 p> 0.05 (NS)
Plat. (103/mm3) 279.8 ± 60.7 230 ± 2.8 1.125 p> 0.05 (NS)
Creatinine (mg/dl) 0.96 ± 0.21 1.0 ± 0.35 0.475 p> 0.05 (NS)
Ca++ (mg/dl) 9.3 ± 0.4 9.7 ± 0.495 1.610 p> 0.05 (NS)
P++ (mg/dl) 3.1 ± 0.4 3.9 ± 0.2 3.00 p< 0.05 (S)
ALP (IU/L) 74.8 ± 15.6 90.0 ± 42.4 1.05 p> 0.05 (NS)
DKK-1 (pg/ml) 2488.5 ± 213.5 2860 ± 70.7 2.374 p< 0.05 (S)
DD=Disease Duration, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, BASMI = Bath Ankylosing Spondylitis Metrology
Index, BASRI-s = Bath Ankylosing Spondylitis Radiology Index-spine, mSASSS = modiﬁed Stoke Ankylosing Spondylitis Spinal Score,
ESR= Erythrocyte Sedimentation Rate, CRP = C-Reactive Protein, Hb %=Hemoglobin %, RBCs = Red Blood Cells, WBCs =White
Blood Cells, Plat. = Platelets, Ca++= Calcium, P++= Phosphorous, ALP = Bone speciﬁc alkaline phosphates, DKK-1 = Dickkopf-1.
a Mean ranks.
b Mann Whitney test.
Figure 2 Regression curve showing signiﬁcant negative correlation between DKK-1 and mSASSS. X-Axis indicates DKK-1 serum level;
y-axis indicates mSASSS, r= 0.926, (p< 0.001). DKK=DKK-1 = Dickkopf-1, mSASSS = modiﬁed Stoke Ankylosing Spondylitis
Spinal Score.
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mSASSS and DKK-1 in AS patients [12]. This may be partially
attributed to inter study differences related to sex, ethnicity,
sample size (studies with a large sample size generally have suf-
ﬁcient power to detect association that may be undetectable in
a smaller size), study design and analysis methods.
On comparing HLA-B27 positive and HLA-B27 negative
there were signiﬁcant increase in disease duration, BASRI-s,mSASSS and decrease DKK-1 levels in HLA-B27 positive ver-
sus HLA-B27 negative (p< 0.05). HLA-B27 transgenic rate
and proteoglycan immumization models of BAL/B/C mice
both develop spinal fusion [28]. Therefore HLA-B27 might
be another factor in the pathophysiology of the joint fusion
and osteophyte formation in ankylosing spondylitis [13], or
HLA-B27 positive might be low DKK-1 producers (Table 2,
Figs. 2 and 3).
Figure 3 Plain X-ray of a male AS patient with complete ankylosis of S/I joints (a), ossiﬁcation of ant. longitudinal ligament and
annulus ﬁbrosis and syndesmophytes (c) with bamboo shape of the spine (b).
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not treated with anti TNF there was no signiﬁcant differences
in DKK-1 levels in both groups (p> 0.05). Our result was
similar to that of Kim et al. [14]. Others observed elevated
DKK-1 serum levels after anti TNF therapy [12]. TNF is a
key proinﬂammatory cytokine in AS, but it is a potent inhib-
itor of bone formation, so it is unlikely to explain the forma-
tion of osteopytes in AS. This is also suggested by clinical
data showing that TNF blockade seems not to affect structural
remodeling of spinal skeleton in AS, which largely indicates
changes due to increased bone apposition [28,29]. The efﬁcacy
of TNF blockers to improve clinical symptoms in AS and their
poor effects on structural remodeling need further researches.
In conclusion, our ﬁndings suggest dysfunction of DKK-1
in patients with AS. However, our study has limitation of
being a cross sectional study with a single measurement of
DKK-1 which did not take into account the possible changing
serum levels over time. Further researches with large number
have to clarify whether there are low and high DKK-1 produc-
ers among AS patients, whether this production is controlled
genetically or by other mechanisms and whether DKK-1 levels
or other Wnt inhibitors can be used to predict fast progression
of new bone formation. Finally this may help in developing
novel treatments to target bone-forming process in AS which
are currently lacking.Conﬂict of interest statement
Authors disclose no conﬂict of interest.
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